...
首页> 外文期刊>Vascular pharmacology >Mechanisms underlying uridine adenosine tetraphosphate-induced vascular contraction in mouse aorta: Role of thromboxane and purinergic receptors
【24h】

Mechanisms underlying uridine adenosine tetraphosphate-induced vascular contraction in mouse aorta: Role of thromboxane and purinergic receptors

机译:尿苷四磷酸腺苷诱导小鼠主动脉血管收缩的潜在机制:血栓烷和嘌呤能受体的作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Uridine adenosine tetraphosphate (Up(4)A), a novel endothelium-derived vasoactive agent, is proposed to play a role in cardiovascular disorders and induces aortic contraction through activation of cyclooxygenases (COXs). We and others demonstrated that activation of A(1) or A(3) adenosine receptors (ARs) results in vascular contraction via thromboxane (TX) A(2) production. However, the mechanisms of Up(4)A-induced vascular contraction in mouse aorta are not understood. We hypothesize that Up(4)A-induced aortic contraction is through COX-derived TXA(2) production, which requires activation of A(1) and/or A(3)AR. Concentration responses to Up(4)A were conducted in isolated aorta. The TXB2 production, a metabolite of TXA(2), was also measured. Up(4)A (10(-9)-10(-5) M) produced a concentration-dependent contraction > 70%, which was markedly attenuated by COX and COX1 but not by COX2 inhibition. Notably, Up(4)A-induced aortic contraction was blunted by both TX synthase inhibitor ozagrel and TXA(2) receptor (TP) antagonist SQ29548. Surprisingly, A(3)AR deletion had no effect on Up(4)A-induced contraction. Moreover, A(1)AR deletion or antagonism as well as A(1)/A(3)AR deletion potentiated Up(4)A-induced aortic contraction, suggesting a vasodilator influence of A(1)AR. In contrast, non-selective purinergic P2 receptor antagonist PPADS significantly blunted Up(4)A-induced aortic contraction to a similar extent as selective P2X(1)R antagonist MRS2159, the latter of which was further reduced by addition of ozagrel. Endothelial denudation almost fully attenuated Up(4)A-induced contraction. Furthermore, Up(4)A (3 mu M) increased TXB2 formation, which was inhibited by either MRS2159 or ozagrel. In conclusion, Up(4)A-induced aortic contraction depends on activation of TX synthase and TP, which partially requires the activation of P2X(1)R but not A(1) or A(3)AR through an endothelium-dependent mechanism. (C) 2015 Elsevier Inc. All rights reserved.
机译:尿苷四磷酸腺苷(Up(4)A),一种新型的内皮源性血管活性剂,被认为在心血管疾病中发挥作用,并通过激活环氧合酶(COXs)诱导主动脉收缩。我们和其他人证明A(1)或A(3)腺苷受体(ARs)的激活通过血栓烷(TX)A(2)产生血管收缩。但是,尚不了解Up(4)A诱导小鼠主动脉血管收缩的机制。我们假设Up(4)A诱导的主动脉收缩是通过COX衍生的TXA(2)产生的,这需要激活A(1)和/或A(3)AR。在孤立的主动脉中进行对Up(4)A的浓度反应。还测量了TXB2的产生,它是TXA(2)的代谢产物。 Up(4)A(10(-9)-10(-5)M)产生的浓度依赖性收缩> 70%,其被COX和COX1显着减弱,但不受COX2抑制。值得注意的是,TX合酶抑制剂奥扎格雷和TXA(2)受体(TP)拮抗剂SQ29548均抑制了Up(4)A诱导的主动脉收缩。令人惊讶的是,A(3)AR删除对Up(4)A诱导的收缩没有影响。此外,A(1)AR删除或拮抗以及A(1)/ A(3)AR删除增强了Up(4)A诱导的主动脉收缩,提示A(1)AR的血管扩张作用。相反,非选择性嘌呤能P2受体拮抗剂PPADS显着减弱了Up(4)A诱导的主动脉收缩,其程度与选择性P2X(1)R拮抗剂MRS2159相似,后者通过加入奥扎格雷进一步降低。内皮剥脱几乎完全减弱了Up(4)A引起的收缩。此外,Up(4)A(3μM)增加了TXB2的形成,这被MRS2159或奥扎格雷抑制。总之,Up(4)A诱导的主动脉收缩取决于TX合酶和TP的激活,这部分需要通过内皮依赖性机制激活P2X(1)R而不激活A(1)或A(3)AR。 。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号